// App-Quantinova.ai

4516 : Long-term outcomes in EV-301 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

Researchers

Presenter

  • Jonathan E. Rosenberg

Principal Investigators

  • Thomas Powles

  • Guru P. Sonpavde

  • Yohann Loriot

  • Ignacio Duran

  • Jae-Lyun Lee

  • Nobuaki Matsubara

  • Christof Vulsteke

  • Daniel E. Castellano

  • Ronac Mamtani

  • Chunzhang Wu

  • Maria Matsangou

  • Mary S. Campbell

  • Daniel P. Petrylak

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Barts Health NHS Trust St Bartholomew's Hospital, London, United Kingdom

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • National Cancer Center Hospital, Tokyo, Japan

  • Center for Oncological Research (CORE), University of Antwerp, Integrated Cancer Center Ghent, Ghent, Belgium

  • Medical Oncology Department. Hospital 12 de Octubre, Madrid, Spain

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Astellas Pharma, Inc., Northbrook, IL

  • Seattle Genetics, Bothell, WA

  • Yale Cancer Center, New Haven, CT

Locations

  • United States

  • United Kingdom

  • France

  • Spain

  • Republic of South Korea

  • Japan

  • Belgium

Companies

  • Astellas Pharma Inc.

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Enfortumab vedotin

  • Paclitaxel

  • vinflunine

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03474107

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved